- Work +41 43 222 10 00
- Fax +41 43 222 15 00
Delenex completed Second Tranche of Series A Financing Round
At the end of February 2012, Delenex Therapeutics AG, a Swiss biotech company developing therapeutic antibody fragments for diseases with high unmet need, successfully completed a Second Tranche of the series A financing round worth CHF 16.7 million, bringing the total A round investment to CHF 30.2 million.
Delenex Therapeutics AG was advised on this transaction by Homburger. The Homburger team was led by partner Dieter Gericke and included associate Emanuel Dettwiler (both Corporate | M&A).
For more information please visit www.homburger.ch